hospira morphine sulfate injection morphine sulfate15 mg/1 ml injection ampoule
pfizer australia pty ltd - morphine sulfate pentahydrate -
hospira morphine sulfate injection morphine sulfate pentahydrate 10 mg/1 ml injection ampoule
pfizer australia pty ltd - morphine sulfate pentahydrate -
hospira morphine sulfate injection morphine sulfate pentahydrate 5 mg/1 ml injection ampoule
pfizer australia pty ltd - morphine sulfate pentahydrate -
hospira ephedrine sulfate injection ephedrine sulfate 30mg/1ml injection ampoule
pfizer australia pty ltd - ephedrine sulfate -
hospira propofol injection propofol 1g/100ml emulsion for injection vial
pfizer australia pty ltd - propofol -
hospira propofol injection propofol 500mg/50ml emulsion for injection vial
pfizer australia pty ltd - propofol -
hospira propofol injection propofol 200mg/20ml emulsion for injection vial
pfizer australia pty ltd - propofol -
hospira cefoxitin sodium powder for injection
hospira pty limited - cefoxitin sodium -
hospira gemcitabine injection 38 mg/ml, 2 g/52.6 ml vial
hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.
hospira gemcitabine injection 38 mg/ml, 1 g/26.3 ml vial
hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.